CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

Zacks Investment Research • 13 hours ago

Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?

CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.

Zacks Investment Research • Feb 23, 2026

CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?

CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.

Zacks Investment Research • Feb 17, 2026

CorMedix Inc. (CRMD) Analyst/Investor Day Transcript

CorMedix Inc. (CRMD) Analyst/Investor Day Transcript

Seeking Alpha • Feb 14, 2026

CorMedix to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March.

GlobeNewsWire • Feb 12, 2026

CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside

CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.

Zacks Investment Research • Feb 11, 2026

CorMedix Therapeutics Announces Share Repurchase Program

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock.

GlobeNewsWire • Feb 2, 2026

CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?

CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.

Zacks Investment Research • Jan 30, 2026

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern.

GlobeNewsWire • Jan 29, 2026

Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?

CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.

Zacks Investment Research • Jan 23, 2026